此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

研究测试两种调理方案,在符合匹配供体同种异体移植资格的患者移植后使用环磷酰胺和甲氨蝶呤单次预防 GVHD (CY-MET-RIC)

2026年11月16日 更新者:Nantes University Hospital

随机 2 期研究在符合匹配供体同种异体移植资格的患者中测试移植后使用环磷酰胺和甲氨蝶呤单次预防移植物抗宿主病的两种调理方案

Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (allo-CSH).

Recently, in the context of semi-identical (=haploidentical) HLA donors, but also of compatible HLA donors, the use of cyclophosphamide (CY) administered in high doses at early post-transplant (PT) (=PTCY) (Days +3 and +4 or +5) has shown excellent control of acute and chronic GVH, even enabling the discontinuation of other immunosuppressive drugs administered after allo-CSH (ciclosporin, mycophenolate mofetyl (MMF) or Cellcept).

This step has already been taken in the context of allo-CSH with myeloablative conditioning (MAC), which is a minoritary conditioning in adults.

However, in the context of allo-CSH with reduced-intensity conditioning (RIC), which predominates in adults, this strategy seems insufficient to prevent the risk of GVHD.

The idea of reducing the use of immunosuppressants in the context of RIC/HLA-compatible transplants seems, however, still relevant, in order to reduce their adverse effects, improve patients' quality of life and enhance the reconstitution of the post-transplant immune system.

研究概览

详细说明

For this reason, the investigators now wish to test the administration of a combination of a high dose of early post-transplant CY (PTCY) and methotrexate (MTX) on days (D) D+1, D+4, D+6, D+11 (doses already performed in MAC transplant prophylaxis), with anti-lymphocyte serum (ALS) with RIC conditioning, without ciclosporin or MMF.

The investigators hypothesize that administration of this PTCY+MTX combination will enable immunosuppressive drugs to be discontinued as early as D+11 post-transplant, compared with the usual average of 3 to 4 months.

研究类型

介入性

注册 (估计的)

82

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 70年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age: ≥ 18 and ≤ 70 years old
  • Patient with hematologic malignancy
  • Indication for HSC allograft with attenuated conditioning
  • Pluripotent stem cell (PSC) engraftment
  • Availability of a 10/10 familial or non-familial HLA compatible donor
  • Consent to the protocol
  • ECOG <=2
  • Woman of childbearing age with negative pregnancy test and on highly effective contraception during treatment and for a period of 12 months after stopping MTX and CY
  • Man of childbearing age with highly effective contraception during treatment and for a period of 6 months after stopping MTX and CY and a period of 12 months after stopping MTX and CY if TBF conditioning regimen arm
  • Negative Hepatitis B, C, HIV serologies
  • Social security affiliation

Exclusion Criteria:

  • History of allograft
  • Patient eligible for myeloablative conditioning (MAC)
  • Bone marrow transplant
  • Other progressive cancerous disease, or antecedent of cancer in the last five years, with the exception of a carcinoma of the skin or a carcinoma in situ of the uterine cole treated and in remission.
  • Progressive psychiatric condition
  • Pregnant or breastfeeding woman,
  • Woman or man of childbearing age with lack of effective contraception
  • Serious and uncontrolled concomitant infection
  • Cardiac: systolic ejection fraction < 50% by transthoracic ultrasound or by isotopic method (isotope gamma angiography), NYHA II, III or IV heart failure, active rhythmic, valvular or ischemic heart disease or anteriority
  • Respiratory with EFR: DLCOc <40% of theoretical
  • Renal: creatinine clearance < 50 ml/min (assessment with MDRD method)
  • Urological: active urinary tract infection, history of acute urothelial toxicity due to cytotoxic chemotherapy or radiotherapy, known obstruction of urinary flow, pre-existing hemorrhagic cystitis
  • Hepatic: transaminases greater than 5 times normal or bilirubin greater than 2 times normal
  • Person protected by law (major under guardianship, curatorship or legal protection)
  • Vaccination against yellow fever in the last year
  • Known or suspected hypersensitivity to rabbit proteins as well as to the active substance and excipients of all investigational and ancillary drugs administered during the study,
  • Contraindication to any of the investigational or adjuvant drugs administered during the study
  • Patient not speaking French

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:(CLO)-BALTIMORE

BALTIMORE conditioning regime for LYMPHOID HEMOPATHY CLO-BALTIMORE conditioning regime for MYELOID HEMOPATHY

15 mg/m² on Day+1 after graft (=Day0) 10 mg/m² 3 days on Day+4/Day+6/Day+11 after graft (=Day0)

其他名称:
  • 甲氨蝶呤

50 mg/kg intravenous 2 days on Day+3/Day+5 after graft (=Day0)

其他名称:
  • CY

Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)

其他名称:
  • 氟达拉滨 巴尔的摩

Conditioning regimen: 14.5 mg/kg intravenous 2 days on Day-6/Day-5 before graft (=Day0)

Conditioning regimen: 2.5 mg/kg intravenous on Day-2 before graft (=Day0)

其他名称:
  • ATG

2 grays on Day-1 before graft (=Day0)

其他名称:
  • 脑外伤

High dose of hematopoietic stem cells derived from peripheral blood on transplantation day (=Day0 graft)

其他名称:
  • 高等学校

Graft nuclear cells CD3+ cells if needed after transplantation

DLI with CD3+ if relapse after transplantation or in prevention of relapse

其他名称:
  • 数据线

Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)

Conditioning regimen: 40 mg/m² intravenous 4 days on Day-5/Day-4/Day-3/Day-2 before graft (=Day0)

其他名称:
  • 氟达拉滨TBF
有源比较器:TBF

Conditioning regimen for LYMPHOID AND MYELOID HEMOPATHY

15 mg/m² on Day+1 after graft (=Day0) 10 mg/m² 3 days on Day+4/Day+6/Day+11 after graft (=Day0)

其他名称:
  • 甲氨蝶呤

50 mg/kg intravenous 2 days on Day+3/Day+5 after graft (=Day0)

其他名称:
  • CY

Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)

其他名称:
  • 氟达拉滨 巴尔的摩

Conditioning regimen: 2.5 mg/kg intravenous on Day-2 before graft (=Day0)

其他名称:
  • ATG

High dose of hematopoietic stem cells derived from peripheral blood on transplantation day (=Day0 graft)

其他名称:
  • 高等学校

Graft nuclear cells CD3+ cells if needed after transplantation

DLI with CD3+ if relapse after transplantation or in prevention of relapse

其他名称:
  • 数据线

Conditioning regimen: 40 mg/m² intravenous 4 days on Day-5/Day-4/Day-3/Day-2 before graft (=Day0)

其他名称:
  • 氟达拉滨TBF

Conditioning regimen: 5 mg/kg Intravenous at Day-6 before graft (=Day0)

Conditioning regimen: 3.2 mg/kg Intravenous 2 days at Day-2 and Day-1 before graft (=Day0)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of grade 3-4 acute GVHD following allo-CSH for all patients and for each conditioning group (Baltimore and TBF).
大体时间:Post-transplant through study completion, an average of 1 year

Estimation of the incidence of grade 3 and 4 acute GVHD following allo-CSH (excluding post-DLI* acute GVHD) according to Mount Sinai criteria.

Post-transplant through study completion, an average of 1 year

次要结果测量

结果测量
措施说明
大体时间
Incidence of engraftment
大体时间:Month 1 post-transplant

Engraftment assessed on hematological reconstitution (number of days of aplasia with PNN <0.5 G/L and platelets < 20 G/L, number of platelet and red cell concentrate transfusions)

Month 1 post-transplant
Overall survival (OS)
大体时间:Post-transplant through study completion, an average of 1 year

survival between day 0 of transplantation and date of death or last follow-up

Post-transplant through study completion, an average of 1 year
Disease-free survival (DFS)
大体时间:Post-transplant through study completion, an average of 1 year

survival between day 0 of transplantation and date of relapse, death or last follow-up

Post-transplant through study completion, an average of 1 year
GVHD and relapse-free survival (GRFS)
大体时间:Post-transplant through study completion, an average of 1 year

relapse-free survival without grade 3-4 acute GVHD or chronic GVHD requiring systemic treatment

Post-transplant through study completion, an average of 1 year
Incidence of acute GVHD grade 2-4
大体时间:Post-transplant through study completion, an average of 1 year

Acute GVH grade 2-4 according to Mount Sinai criteria

Post-transplant through study completion, an average of 1 year
Incidence of chronic GVHD
大体时间:From month 3 post-transplant through study completion, an average of 1 year

Chronic GVHD according to NCI criteria

From month 3 post-transplant through study completion, an average of 1 year
Incidence of corticoresistant acute GVHD
大体时间:Post-transplant through study completion, an average of 1 year

Acute corticoresistant GVHD according to the criteria of Mohty et al. defined by :

  • worsening/progression of disease after 3 days of 2mg/kg/day systemic corticosteroid therapy with methylprednisolone (or equivalent),
  • non-improvement of disease after 7 days of 2mg/kg/day systemic corticosteroid therapy with methylprednisolone (or equivalent),
  • disease progression to a new organ after treatment with 1mg/kg/day methylprednisolone (or equivalent) in the case of cutaneous or gastrointestinal GVHD or,
  • recurrence of acute GVHD during or after the corticosteroid reduction phase
Post-transplant through study completion, an average of 1 year
Incidence of non-relapse mortality (NRM)
大体时间:Post-transplant through study completion, an average of 1 year

any death unrelated to relapse or disease progression

Post-transplant through study completion, an average of 1 year
Incidence of relapse
大体时间:Post-transplant through study completion, an average of 1 year

any documented disease recurrence

Post-transplant through study completion, an average of 1 year
Chimerism
大体时间:At Month1, Month2, Month3, Month6, Month12 post-transplant

Total donor or mixed chimerism. Total donor chimerism = result >95% donor CD3+ cells. Mixed chimerism = result >5% and <95% donor CD3+ cells.

At Month1, Month2, Month3, Month6, Month12 post-transplant
Immune reconstitution
大体时间:At Month3, Month6, Month9, Month12 post-transplant

T, NK, B lymphocytes and monocytes

At Month3, Month6, Month9, Month12 post-transplant
Grade 3 and 4 post-transplant adverse events
大体时间:Post-transplant through study completion, an average of 1 year

Grade 3 and 4 post-transplant adverse events (dates of occurrence) (NCI CTCAE criteria, version number 5)

Post-transplant through study completion, an average of 1 year
Incidence of viral, bacteriological, fungal and parasitic infections
大体时间:Post-transplant through study completion, an average of 1 year

Infections: viral (CMV, EBV, BKV, adenovirus), bacteriological, fungal and parasitic

Post-transplant through study completion, an average of 1 year

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Marie-Anne COUTURIER, MD、University Hospital, Brest
  • 首席研究员:Sylvain THEPOT, MD、University Hospital, Angers

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年7月18日

初级完成 (估计的)

2029年10月18日

研究完成 (估计的)

2030年7月18日

研究注册日期

首次提交

2024年1月24日

首先提交符合 QC 标准的

2024年2月1日

首次发布 (实际的)

2024年2月12日

研究记录更新

最后更新发布 (实际的)

2026年11月19日

上次提交的符合 QC 标准的更新

2026年11月16日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅